ArticlePharmaceuticals (Basel, Switzerland)2023
Process to Remove the Size Variants Contained in the Antibody-Chelator Complex PCTA-NCAB001 for Radiolabeling with Copper-64.
Yukie Yoshii, Hiroki Matsumoto, Chika Igarashi, Tomoko Tachibana, Fukiko Hihara, Mitsuhiro Shinada, Atsuo Waki, Sei Yoshida, Kenichiro Naito, Kimiteru Ito and 3 more
Open access · goldAbstract read
In one paragraphArticle in Pharmaceuticals (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 70% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed, 0 citations in OpenAlex.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
13 authors at 5 institutions in 1 country.
Yukie YoshiiInstitute for Quantum Medical Science, National Institutes for Quantum Science and Technology, Chiba 263-8555, Japan.
Hiroki MatsumotoInstitute for Quantum Medical Science, National Institutes for Quantum Science and Technology, Chiba 263-8555, Japan.
Chika IgarashiInstitute for Quantum Medical Science, National Institutes for Quantum Science and Technology, Chiba 263-8555, Japan.
Tomoko TachibanaInstitute for Quantum Medical Science, National Institutes for Quantum Science and Technology, Chiba 263-8555, Japan.
Fukiko HiharaInstitute for Quantum Medical Science, National Institutes for Quantum Science and Technology, Chiba 263-8555, Japan.
Mitsuhiro ShinadaInstitute for Quantum Medical Science, National Institutes for Quantum Science and Technology, Chiba 263-8555, Japan.ORCID 0000-0003-4244-8914 Atsuo WakiInstitute for Quantum Medical Science, National Institutes for Quantum Science and Technology, Chiba 263-8555, Japan.
Sei YoshidaDepartment of Research, NanoCarrier Co., Ltd., Tokyo 104-0031, Japan.
Kenichiro NaitoDepartment of Research, NanoCarrier Co., Ltd., Tokyo 104-0031, Japan.
Kimiteru ItoDepartment of Diagnostic Radiology, National Cancer Center Hospital, Tokyo 104-0045, Japan.ORCID 0000-0003-0905-6767 Tatsuya HigashiInstitute for Quantum Medical Science, National Institutes for Quantum Science and Technology, Chiba 263-8555, Japan.
Hiroaki KuriharaDepartment of Diagnostic Radiology, Kanagawa Cancer Center, Yokohama 241-8515, Japan.
Kanagawa Prefectural Hospital Organization · JPNational Institutes for Quantum Science and Technology · JPNanoCarrier (Japan) · JPToho University · JPTokyo National Hospital · JP
Funding
Japan Agency for Medical Research and Development 20 cm0106479h0001Japan Agency for Medical Research and Development 22lk0201159h0001Japan Society for the Promotion of Science KAKENHI 19H03609
6 · The paper itselfAbstract
Understanding the physicochemical properties of antibody-drug conjugates is critical to assess their quality at manufacturing and monitor them during subsequent storage. For radiometal-antibody complexes, it is important to control the properties of the antibody-chelator conjugate to maintain the quality of the final product. We have been developing
Indexed as
antibody–chelator conjugatesantibody–drug conjugateschromatographyhydrophobic interaction chromatographymulti-angle light scatteringsize exclusion
Identifiers
PMID37895812
PMCPMC10610008
OpenAlexW4386996284
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390